COLLABORATIVE FOR EVIDENCE-BASED MEDICINES

Lobbying Spend

—

Filings

Firms Hired

Active Period

2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	1	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
FAEGRE DRINKER BIDDLE & REATH LLP	—	1

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
No government targets were reported in these filings.

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	1

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 6509119th Congress

SAFE Drugs Act of 2025

Cited source text and reported amounts

Drug compounding issues; SAFE Drugs Act (H.R. 6509 / S. 3794)

Client expense: — · Firm income: —

Matched citations: H.R. 6509

S. 3794119th Congress

SAFE Drugs Act of 2026

Cited source text and reported amounts

Drug compounding issues; SAFE Drugs Act (H.R. 6509 / S. 3794)

Client expense: — · Firm income: —

Matched citations: S. 3794

COLLABORATIVE FOR EVIDENCE-BASED MEDICINES — Lobbying Disclosure | Poliscope